Zouina Sarfraz, Postdoctoral Research Fellow in Oncology at the Miami Cancer Institute, shared a post on LinkedIn:
“Treatment-free survival is increasingly recognized as a meaningful clinical endpoint in metastatic NSCLC.
Our newly published editorial in the Journal of Thoracic Disease critically examines first-line nivolumab plus ipilimumab and explores how outcomes should be interpreted beyond PD-L1 expression alone.
As immunotherapy strategies continue to evolve, refining how we define durable clinical benefit remains essential.
Grateful for the mentorship of Dr. Manmeet Ahluwalia and the opportunity to collaborate with Dr. Vamsi Velcheti.”
Title: Treatment-free survival with first-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: a critical analysis beyond PD-L1 expression
Authors: Zouina Sarfraz, Vamsidhar Velcheti, Manmeet S. Ahluwalia
Read The Full Article
Other articles about NSCLC on OncoDaily.